Cellular engineering for the treatment of metabolic disorders: prospects for therapy in diabetes.
Significant advances in the areas of identification of disease susceptibility genes and gene transfer technologies have fueled new initiatives in cellular engineering as a means for treating metabolic disease. This article utilizes new findings from such work as the blueprint for a discussion of the prospects for gene therapy in diabetes mellitus.
Gifford Laboratories for Diabetes Research, University of Texas Southwestern Medical Center, Dallas 75235.
C B
CB
Newgard
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007332:Insulin Infusion Systems; D007333:Insulin Resistance / Q000235:genetics*; D007340:Insulinoma / Q000378:metabolism; D051379:Mice; D051381:Rats; D014162:Transfection
D000324:Adrenocorticotropic Hormone; D005947:Glucose